These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 4084347)

  • 1. [Bioavailability and tolerance of xanthinol nicotinate depot preparations. Comparison of a conventional 500 mg xanthinol nicotinate depot tablet with new 500 mg and 1 g depot tablets].
    von Schrader HW; Buscher G; Dierdorf D; Freytag A; Mügge H; Wolf D
    Arzneimittelforschung; 1985; 35(9):1468-72. PubMed ID: 4084347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effects of placebo and plain and slow-release tablets of xanthinol nicotinate on exercise tolerance in normal human subjects.
    Sharma PL
    Int J Clin Pharmacol Biopharm; 1978 Jan; 16(1):19-21. PubMed ID: 631966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xanthinol nicotinate in the management of leg ulcers associated with haemoglobinopathies.
    Afifi AM; Adnan M; Taha M; Amasha ME
    Curr Med Res Opin; 1979; 6(5):309-13. PubMed ID: 540521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug therapy of hyperlipemia. Experiences with xanthinol nicotinate retard-capsules in a general practice].
    Klimm HD
    Med Monatsschr; 1976 Apr; 30(4):178-80. PubMed ID: 958145
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical trial of xanthinol nicotinate in delayed form in the treatment of arteritis of the lower limbs].
    Niquet G; Dupont T
    Lille Med; 1976 Jan; 21(1 suppl 1):13-5. PubMed ID: 1256225
    [No Abstract]   [Full Text] [Related]  

  • 6. Xanthinol nicotinate in peripheral vascular disease.
    Davis E; Rozov H
    Practitioner; 1975 Dec; 215(1290):793-8. PubMed ID: 772653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of steady state serum theophylline concentrations in healthy volunteers after dosing with Euphyllin retard and PulmiDur.
    Karlsson S; Lührmann B; Bahner ML; Schulz HU
    Int J Clin Pharmacol Ther Toxicol; 1987 Jun; 25(6):342-6. PubMed ID: 3623739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of chronic arterial vascular disorders with Complamin and Complamin retard].
    Musil HE
    Med Welt; 1973 Jan; 24(3):103-13. PubMed ID: 4617835
    [No Abstract]   [Full Text] [Related]  

  • 9. [Human placental lactogen (HPL) levels in the maternal serum following long-term intake of xantinol nicotinate (Complamin Retard) (author's transl)].
    Sérey CT; Saling E
    Z Geburtshilfe Perinatol; 1980 Aug; 184(4):283-9. PubMed ID: 7008399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.
    Schuppan D; Molz KH; Staib AH; Rietbrock N
    Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):223-7. PubMed ID: 7251238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Absolute bioavailability of theophylline (Euphylline)].
    Somogyi A; Gugler R
    Fortschr Med; 1980 Nov; 98(43):1707-10. PubMed ID: 7450653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Results of a long-term study on the therapeutic effectiveness of xanthinol nicotinate in chronic hepatopathies].
    Dohrmann RE; Kessel ME
    Z Allgemeinmed; 1975 Sep; (26):1167-72. PubMed ID: 1226797
    [No Abstract]   [Full Text] [Related]  

  • 13. Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of xanthinol in human plasma and its application in a bioequivalence study of xanthinol nicotinate tablets.
    Liu HQ; Su MX; Di B; Hang TJ; Hu Y; Tian XQ; Zhang YD; Shen JP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Sep; 873(1):20-6. PubMed ID: 18718822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy of hyperlipidemia with xanthinol nicotinate as opposed to low fat diet].
    Baumann J; Martschick R
    Med Welt; 1982 Jan; 33(4):139-41. PubMed ID: 7062844
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacological evaluation of xanthinol nicotinate (complamin).
    Galal E; Moustafa M; el-Gohary N; el-Mahdy SA; el-S Ali HI; Radwan AG
    J Egypt Med Assoc; 1976; 59(1-2):141-9. PubMed ID: 1032367
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of xanthinol nicotinate treatment on platelet aggregation.
    Seidel G; Endell W
    Int J Clin Pharmacol Biopharm; 1977 Mar; 15(3):139-43. PubMed ID: 844933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The absolute bioavailability of a new pediatric sustained release theophylline tablet, when given as whole or divided tablets.
    Jonkman JH; van der Boon WJ; Schoenmaker R; Holtkamp A; Thürkow-Luikens AJ
    Int J Clin Pharmacol Ther Toxicol; 1984 Sep; 22(9):506-10. PubMed ID: 6500770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system.
    González MA; Straughan AB
    Clin Ther; 1994; 16(5):804-14. PubMed ID: 7859239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of nicotinic acid and xanthinol nicotinate on human memory in different categories of age. A double blind study.
    Loriaux SM; Deijen JB; Orlebeke JF; De Swart JH
    Psychopharmacology (Berl); 1985; 87(4):390-5. PubMed ID: 3936095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The influence of xanthinol nicotinate and of a hyperosmolar solution on the motility of the colon].
    Willmen HR; Kogel H
    Int J Clin Pharmacol Biopharm; 1976 Mar; 13(2):133-8. PubMed ID: 1254378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.